Agomelatine in Depressive Disorders: Its Novel Mechanisms of Action

Srinivasan, Venkataramanujan and Zakaria, Rahimah and Othman, Zahiruddin and Lauterbach, Edward C. and Acuña-Castroviejo, Darío (2012) Agomelatine in Depressive Disorders: Its Novel Mechanisms of Action. Journal of Neuropsychiatry and Clinical Neurosciences, 24 (3). pp. 290-308. ISSN 0895-0172

PDF - Accepted Version Restricted to Repository staff only Download (770kB)

Abstract

Disruptions in sleep and sleep–wake cycle regulation have been identified as one of the main causes for the pathophysiology of depressive disorders. The search has been on for the identification of an ideal antidepressant that could improve both sleep disturbances and depressive symptomatology. Melatonin, the major hormone of the pineal gland, has been shown to improve sleep and is involved in the regulation of the sleep–wake cycle. Identification of high concentrations of MT1 and MT2 melatonergic receptors in the suprachiasmatic nucleus of the anterior hypothalamus, the structure concerned with regulation of circadian rhythms and sleep–wake cycles, has led to the development of melatonergic agonists with greater potency and longer durations of action. Agomelatine is one such melatonergic agonist that acts specifically on MT1/MT2 melatonergic receptors and at the same time exhibits 5-HT2C antagonism, a property that is utilized by current antidepressants that are in clinical use. Agomelatine has been shown to be effective in a number of animal models of depression.

Item Type:	Article
Subjects:	R Medicine > RC Internal medicine > RC0321 Neuroscience. Biological psychiatry. Neuropsychiatry
Divisions:	Kampus Kesihatan (Health Campus) > Pusat Pengajian Sains Perubatan (School of Medical Sciences) > Article Zoom Profil Pakar (Expert Profile) > Zahiruddin Othman (Medical Sciences)
Depositing User:	Administrator Automasi
Date Deposited:	30 May 2019 01:32
Last Modified:	30 May 2019 01:32
URI:	http://eprints.usm.my/id/eprint/44437

Actions (login required)

View Item